Novo Nordisk (NVO) and Eli Lilly (LLY) manufacture the top three weight loss drugs on the market, but heightened demand is ...

Novo said supply of Wegovy and Ozempic is in good shape after the drugs were removed from the FDA’s shortage list last week.

That means it aspires to directly compete with the likes of Eli Lilly and Novo Nordisk, the big pharmas that currently split the bulk of the market for weight loss drugs. Per new data it presented at ...

At least 25% body weight loss occurred in 43% taking the highest dose ... Jastreboff reported disclosures with Amgen, ...

Healthcare giant Eli Lilly (NYSE: LLY) has been trading at an inflated valuation for some time thanks to excitement around ...

Novo Nordisk reported better-than-expected third-quarter sales for its weight-loss drug Wegovy, calming investor concerns ...

Novo Nordisk (NVO) posts Q3 sales for its weight loss drug Wegovy, contrasting rival Eli Lilly's (LLY) quarterly miss for its obesity drug, Zepbound. Read more here.

Novo Nordisk reported strong sales for its weight-loss drug Wegovy, surpassing analyst expectations and calming investor ...

Some patients are using lower-than-recommended dosages of generic weight-loss drugs to slim down while saving ... Last week, ...

Health-care companies ticked down as enthusiasm about a new class of weight-loss drugs continued to wane. Viking Therapeutics slid, giving up initial gains, after the biotech posted data on its oral ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...